Skip to main content
Northwestern University Feinberg School of Medicine
Department of Medicine
Skip to main content

Infectious Diseases Clinical Trials

The following searchable list includes all the Division of Infectious Diseases - Department of Medicine clinical trials currently looking for participants. Please feel free to contact us with inquiries about any of our ongoing research.

Trials
Randomized Trial to Prevent Vascular Events in HIV – REPRIEVE (A5332)/ A5333s: Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers: Mechanistic Substudy of REPRIEVE/A5361s: Pitavastatin to REduce Physical Function Impairment and Frailty in HIV (PREPARE)
People infected wi…
People infected with HIV are at risk for cardiovascular disease (CVD). REPRIEVE is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months. The trial is testing the effect of statin therapy on preventing heart disease and death in HIV-infected persons on HIV medications who do not meet guidelines for starting statins. HIV causes inflammation (irritation) inside the body that may contribute to diseases such as heart disease. HIV medications can lower inflammation, however the levels of inflammation can remain higher compared to people who are not infected with HIV. Statins, such as pitavastatin, are medications that are used to lower the levels of cholesterol and triglycerides (fat in the blood) and have been shown to lower levels of inflammation and heart disease.
• HIV infected men and women between the ages of 40 and 75
• On anti-HIV medications for at least 6 months
• CD4 cell count greater than 100
• No history of cardiovascular disease, such as heart attack, stroke, etc.
• No history of cancer in the last 3 years
• Not currently using a statin drug
Taiwo, Babafemi OTaiwo, Babafemi O
NCT02344290 STU00200323
More Info

For more information on this study please contact us:

Berzins, Baiba Ingrida 312 695 5012
Copy
ACTG A5354: Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
This study will include people who have very recently been infected with HIV and will start them on anti-HIV (antiretroviral) drugs right away …
This study will include people who have very recently been infected with HIV and will start them on anti-HIV (antiretroviral) drugs right away to see how this may change HIV’s impact on the body.
• Men and women, at least 18 years old
• Have certain lab tests done that confirm very early HIV infection (ie. before the blood shows that antibodies have been made, or just at the time antibodies are starting to be found in the blood)
• Be willing to take drugs to treat HIV right away.
Taiwo, Babafemi OTaiwo, Babafemi O
NCT02859558 STU00203124
More Info

For more information on this study please contact us:

Berzins, Baiba Ingrida 312 695 5012
Copy
ACTIV-2/A5401: Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID)

ACTIV-2/A5401 is a master protocol to evaluate the safety and efficacy ofinvestigational agents for the treatment of symptomatic non-hospitalized adultswith COVID-19.

This study is being done to…

ACTIV-2/A5401 is a master protocol to evaluate the safety and efficacy ofinvestigational agents for the treatment of symptomatic non-hospitalized adultswith COVID-19.

This study is being done to rapidly and efficiently evaluate multiple potentialtherapeutics for COVID-19 in an outpatient setting.

Duration of study: 28 days of intensive follow-up, followedby limited follow-up through 24 weeks.

  • Ambulatory (non-hospitalized) adult (18 years or older)
  • Active COVID-19 infection within 7 days prior to Entry
  • At least one typical COVID-19 symptom for within 10 days prior to Entry, plus one the following symptoms present within 48 hours of entry:

–Fever or feeling feverish, cough, shortness of breath atrest or with activity, sore throat, body or muscle pain, fatigue, headache,chills

Taiwo, Babafemi OTaiwo, Babafemi O
  • Map it 201 E. Huron St.
    Chicago, IL
NCT04518410 STU00213144
More Info
COVID

For more information on this study please contact us:

Berzins, Baiba Ingrida +1 312 695 5012
Copy
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19

The AZD1222 COVID-19VACCINE Study is researching an investigational vaccin…

The AZD1222 COVID-19VACCINE Study is researching an investigational vaccine for the prevention of COVID-19, the disease caused by the new coronavirus (SARS-CoV-2). The studywill see how safe the investigational vaccine is and how well it works.

Participants will berandomly assigned (by chance) to receive 2 injections of either theinvestigational vaccine or placebo.

If you take part, you willbe in the study for approximately 2 years and will require up to 10 visits toour study center. Additional visits may be required if you develop symptoms ofCOVID-19 during the study. Your health will be monitored carefully by a team ofdoctors and nurses throughout the study. The study injections, healthassessments, and medical tests related to the study will be provided at no costto you.

You may be able to take part in the AZD1222 COVID-19 VACCINE Study if you:

- Are 18 years of age or older

- Are in good or stable health (you may have an underlying medical condition and still take part, if your disease is stable)

- Have an increased risk of getting COVID-19

- Do not have a previously confirmed diagnosis of COVID-19

Taiwo, Babafemi OTaiwo, Babafemi O
  • Map it 676 N. Saint Clair St. Suite 940
    Chicago, IL
STU00213385
More Info
COVID Vaccine

For more information on this study please contact us:

Berzins, Baiba Ingrida +1 312 695 5012
Copy
Back to top